The Effect of Metabolic Syndrome on Colorectal Cancer Prognosis after Primary Surgery

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin. 2018;68(6):394–424. doi: 10.3322/caac.21492.
   PubMed Web of Science ®Google Scholar
• Peng D, Liu X-Y, Cheng Y-X, Tao W, Cheng Y. Improvement of diabetes mellitus after colorectal cancer surgery: A retrospective study of predictive factors for type 2 diabetes mellitus remission and overall survival. Front Oncol. 2021;11:694997. doi: 10.3389/fonc.2021.694997.
   PubMed Web of Science ®Google Scholar
• Hashiguchi Y, Muro K, Saito Y, Ito Y, Ajioka Y, Hamaguchi T, Hasegawa K, Hotta K, Ishida H, Ishiguro M, Japanese Society for Cancer of the Colon and Rectum, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2020;25(1):1–42. doi: 10.1007/s10147-019-01485-z.
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Kawada K, Obama K. Inflammation-related biomarkers for the prediction of prognosis in colorectal cancer patients. IJMS. 2021;22(15):8002. doi:10.3390/ijms22158002
   Web of Science ®Google Scholar
• Mooi J, Chionh F, Savas P, Da Gama Duarte J, Chong G, Brown S, Wong R, Price TJ, Wann A, Skrinos E, et al. Dual antiangiogenesis agents bevacizumab plus trebananib, without chemotherapy, in first-line treatment of metastatic colorectal cancer: results of a Phase II study. Clin Cancer Res. 2021;27(8):2159–67. doi: 10.1158/1078-0432.CCR-20-2714.
   PubMed Web of Science ®Google Scholar
• Peng D, Cheng YX, Cheng Y. Improved overall survival of colorectal cancer under multidisciplinary team: A meta-analysis. Biomed Res Int. 2021;2021:5541613. doi: 10.1155/2021/5541613.
   PubMed Web of Science ®Google Scholar
• Weihe P, Weihrauch-Blüher S. Metabolic syndrome in children and adolescents: Diagnostic criteria, therapeutic options and perspectives. Curr Obes Rep. 2019;8(4):472–9. doi: 10.1007/s13679-019-00357-x.
   PubMed Web of Science ®Google Scholar
• Engin A. The definition and prevalence of obesity and metabolic syndrome. Adv Exp Med Biol. 2017;960:1–17. doi: 10.1007/978-3-319-48382-5_1.
   PubMed Web of Science ®Google Scholar
• Xanthakis V, Sung JH, Samdarshi TE, Hill AN, Musani SK, Sims M, Ghraibeh KA, Liebson PR, Taylor HA, Vasan RS, et al. Relations between subclinical disease markers and type 2 diabetes, metabolic syndrome, and incident cardiovascular disease: the Jackson Heart Study. Diabetes Care. 2015;38(6):1082–8. doi:10.2337/dc14-2460
   PubMed Web of Science ®Google Scholar
• Teklu M, Zhou W, Kapoor P, Patel N, Dey AK, Sorokin AV, Manyak GA, Teague HL, Erb-Alvarez JA, Sajja A, et al. Metabolic syndrome and its factors are associated with noncalcified coronary burden in psoriasis: An observational cohort study. J Am Acad Dermatol. 2021;84(5):1329–38. doi:10.1016/j.jaad.2020.12.044
   PubMed Web of Science ®Google Scholar
• Zeraattalab-Motlagh S, Jayedi A, Shab-Bidar S. The effects of resveratrol supplementation in patients with type 2 diabetes, metabolic syndrome, and nonalcoholic fatty liver disease: an umbrella review of meta-analyses of randomized controlled trials. Am J Clin Nutr. 2021:114(5):1675–85. doi:10.1093/ajcn/nqab250
   PubMed Web of Science ®Google Scholar
• Winkels RM, Heine-Bröring RC, van Zutphen M, van Harten-Gerritsen S, Kok DE, van Duijnhoven FJ, Kampman E. The COLON study: Colorectal cancer: Longitudinal, Observational study on Nutritional and lifestyle factors that may influence colorectal tumour recurrence, survival and quality of life. BMC Cancer. 2014;14:374. doi:10.1186/1471-2407-14-374
   Google Scholar
• Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care. 2012;35(11):2402–11. doi:10.2337/dc12-0336
   PubMed Web of Science ®Google Scholar
• Han F, Wu G, Zhang S, Zhang J, Zhao Y, Xu J. The association of metabolic syndrome and its components with the incidence and survival of colorectal cancer: A systematic review and meta-analysis. Int J Biol Sci. 2021;17(2):487–97. doi: 10.7150/ijbs.52452.
   PubMed Web of Science ®Google Scholar
• Li X, Chen H, Wang G, et al. Metabolic syndrome components and the risk of colorectal cancer: a population-based prospective study in Chinese men. Front Oncol. 2019;9:1047.
   PubMed Web of Science ®Google Scholar
• Ahmed RL, Schmitz KH, Anderson KE, Rosamond WD, Folsom AR. The metabolic syndrome and risk of incident colorectal cancer. Cancer. 2006;107(1):28–36. doi: 10.1002/cncr.21950.
   PubMed Web of Science ®Google Scholar
• Bhome R, Peppa N, Karar S, McDonnell D, Mirnezami A, Hamady Z. Metabolic syndrome is a predictor of all site and liver-specific recurrence following primary resection of colorectal cancer: Prospective cohort study of 1006 patients. Eur J Surg Oncol. 2021;47(7):1623–8. doi:10.1016/j.ejso.2020.12.016
   PubMed Web of Science ®Google Scholar
• Shen Z, Ye Y, Bin L, Yin M, Yang X, Jiang K, Wang S. Metabolic syndrome is an important factor for the evolution of prognosis of colorectal cancer: survival, recurrence, and liver metastasis. Am J Surg. 2010;200(1):59–63. doi: 10.1016/j.amjsurg.2009.05.005.
   PubMed Web of Science ®Google Scholar
• Silva A, Pereira SS, Monteiro MP, Araújo A, Faria G. Effect of metabolic syndrome and individual components on colon cancer characteristics and prognosis. Front Oncol. 2021;11:631257. doi: 10.3389/fonc.2021.631257.
   PubMed Web of Science ®Google Scholar
• Li Y, Zhao J, Wu X, Zhang Y, Jin Y, Cai W. Clinical and genomic characteristics of metabolic syndrome in colorectal cancer. Aging (Albany NY). 2021;13(4):5442–60. doi: 10.18632/aging.202474.
   PubMedGoogle Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. doi: 10.1371/journal.pmed.1000097.
   PubMed Web of Science ®Google Scholar
• Punt CJA, Buyse M, Köhne C-H, Hohenberger P, Labianca R, Schmoll HJ, Påhlman L, Sobrero A, Douillard J-Y. Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials. J Natl Cancer Inst. 2007;99(13):998–1003. doi:10.1093/jnci/djm024.
   PubMed Web of Science ®Google Scholar
• Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5. doi: 10.1007/s10654-010-9491-z.
   PubMed Web of Science ®Google Scholar
• Croft B, Reed M, Patrick C, Kovacevich N, Voutsadakis IA. Diabetes, obesity, and the metabolic syndrome as prognostic factors in stages I to III colorectal cancer patients. J Gastrointest Cancer. 2019;50(2):221–9. doi: 10.1007/s12029-018-0056-9.
   PubMed Web of Science ®Google Scholar
• You J, Liu W-Y, Zhu G-Q, Wang O-C, Ma R-M, Huang G-Q, Shi K-Q, Guo G-L, Braddock M, Zheng M-H, et al. Metabolic syndrome contributes to an increased recurrence risk of non-metastatic colorectal cancer. Oncotarget. 2015;6(23):19880–90. doi:10.18632/oncotarget.4166
   PubMedGoogle Scholar
• You J, Zhang H, Shen Y, Chen C, Liu W, Zheng M, Poucke SV, Guo G, Huang Z. Impact of platelet to lymphocyte ratio and metabolic syndrome on the prognosis of colorectal cancer patients. OTT. 2017;10:2199–208. doi:10.2147/OTT.S132621
   Web of Science ®Google Scholar
• Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statist Med. 1998;17(24):2815–34. doi:10.1002/(sici)1097-0258(19981230)17:24 < 2815::aid-sim110 > 3.0.co;2-8
   PubMed Web of Science ®Google Scholar
• Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16. doi: 10.1186/1745-6215-8-16.
   PubMed Web of Science ®Google Scholar
• Ioannidis JP. Interpretation of tests of heterogeneity and bias in meta-analysis. J Eval Clin Pract. 2008;14(5):951–7. doi: 10.1111/j.1365-2753.2008. 00986. x.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60. doi: 10.1136/bmj.327.7414.557.
   PubMed Web of Science ®Google Scholar
• Lohsiriwat V, Pongsanguansuk W, Lertakyamanee N, Lohsiriwat D. Impact of metabolic syndrome on the short-term outcomes of colorectal cancer surgery. Dis Colon Rectum. 2010;53(2):186–91. doi:10.1007/DCR.0b013e3181bdbc32
   PubMed Web of Science ®Google Scholar
• Akinyemiju T, Sakhuja S, Vin-Raviv N. In-hospital mortality and post-surgical complications among cancer patients with metabolic syndrome. Obes Surg. 2018;28(3):683–92. doi: 10.1007/s11695-017-2900-6.
   PubMed Web of Science ®Google Scholar
• Zhou C-J, Cheng Y-F, Xie L-Z, Hu W-L, Chen B, Xu L, Huang C-J, Cai M, Shen X, Liu C-B, et al. Metabolic syndrome, as defined based on parameters including visceral fat area, predicts complications after surgery for rectal cancer. Obes Surg. 2020;30(1):319–26. doi: 10.1007/s11695-019-04163-1.
   PubMed Web of Science ®Google Scholar
• Shariq OA, Hanson KT, McKenna NP, Kelley SR, Dozois EJ, Lightner AL, Mathis KL, Habermann EB. Does metabolic syndrome increase the risk of postoperative complications in patients undergoing colorectal cancer surgery? Dis Colon Rectum. 2019;62(7):849–58. doi: 10.1097/DCR.0000000000001334.
   PubMed Web of Science ®Google Scholar
• Cheng H-C, Chang T-K, Su W-C, Tsai H-L, Wang J-Y. Narrative review of the influence of diabetes mellitus and hyperglycemia on colorectal cancer risk and oncological outcomes. Transl Oncol. 2021;14(7):101089. doi: 10.1016/j.tranon.2021.101089.
   PubMed Web of Science ®Google Scholar
• Chen X, Yi CH, Ya KG. Renin-angiotensin system inhibitor use and colorectal cancer risk and mortality: A dose-response meta analysis. J Renin Angiotensin Aldosterone Syst. 2020;21(3):1470320319895646. doi: 10.1177/1470320319895646.
   Web of Science ®Google Scholar
• Hirabara SM, Gorjão R, Vinolo MA, Rodrigues AC, Nachbar RT, Curi R. Molecular targets related to inflammation and insulin resistance and potential interventions. J Biomed Biotechnol. 2012;2012:379024. doi: 10.1155/2012/379024.
   PubMedGoogle Scholar
• Liu JJ, Druta M, Shibata D, Coppola D, Boler I, Elahi A, Reich RR, Siegel E, Extermann M. Metabolic syndrome and colorectal cancer: is hyperinsulinemia/insulin receptor-mediated angiogenesis a critical process? J Geriatr Oncol. 2014;5(1):40–8. doi:10.1016/j.jgo.2013.11.004
   PubMed Web of Science ®Google Scholar